Should I buy or sell Knight Therapeutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Knight Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" KHTRF shares. View KHTRF analyst ratings or view top-rated stocks .

What is Knight Therapeutics' stock price target for 2024?

1 analysts have issued 12 month price objectives for Knight Therapeutics' stock. Their KHTRF share price targets range from $7.50 to $7.50. On average, they predict the company's stock price to reach $7.50 in the next year. This suggests a possible upside of 79.0% from the stock's current price. View analysts price targets for KHTRF or view top-rated stocks among Wall Street analysts .

How have KHTRF shares performed in 2024?

Knight Therapeutics' stock was trading at $3.96 on January 1st, 2024. Since then, KHTRF stock has increased by 5.8% and is now trading at $4.19. View the best growth stocks for 2024 here .

Are investors shorting Knight Therapeutics?

Knight Therapeutics saw a decline in short interest in the month of March. As of March 15th, there was short interest totaling 209,300 shares, a decline of 10.4% from the February 29th total of 233,600 shares. Based on an average daily trading volume, of 6,200 shares, the short-interest ratio is presently 33.8 days. View Knight Therapeutics' Short Interest .

When is Knight Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our KHTRF earnings forecast .

How do I buy shares of Knight Therapeutics?

Shares of KHTRF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:KHTRF

Knight Therapeutics (KHTRF) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Free KHTRF Stock Alerts

$4.19

-0.10 (-2.33%)

(As of 04/19/2024 ET)

Compare

Today's Range: $4.19
▼
$4.19
50-Day Range: $3.88
▼
$4.29
52-Week Range: $3.20
▼
$4.29

Volume: 100 shs
Average Volume: 7,218 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $7.50

Stock Analysis Analyst Forecasts Chart Headlines Short Interest

Get Knight Therapeutics alerts:

Ad Crypto 101 Media

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

About Knight Therapeutics Stock (OTCMKTS:KHTRF)

Knight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma. The company provides Ladecvina for multiple myeloma and myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Palbocil for breast cancer; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Dolufevir for HIV infection; Exelon for dementia; and Ibsrela for irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for vasomotor symptoms; Fibridoner for idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, it finances other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is headquartered in Montreal, Canada.

KHTRF Stock Price History

30 days | 90 days | 365 days | Advanced Chart

KHTRF Stock News Headlines

March 28, 2024 | finance.yahoo.com

Knight Therapeutics Inc. ranks on The Globe and Mail’s fifth-annual Women Lead Here benchmark of executive gender diversity

March 24, 2024 | finance.yahoo.com

Knight Therapeutics Inc. Just Missed Earnings With A Surprise Loss - Here Are Analysts Latest Forecasts

April 20, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

March 21, 2024 | globenewswire.com

Knight Therapeutics Reports Fourth Quarter and Year-End 2023 Results

March 14, 2024 | baystreet.ca

Knight Therapeutics Inc.

March 14, 2024 | globenewswire.com

Notice of Knight Therapeutics' Fourth Quarter and Year End 2023 Results Conference Call

March 6, 2024 | realmoney.thestreet.com

Knight Therapeutics price target raised by C$0.50 at Raymond James

February 28, 2024 | globenewswire.com

Knight Therapeutics Inc. Celebrates its First Decade of Success

April 20, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

February 21, 2024 | globenewswire.com

Knight Therapeutics Announces Regulatory Submission of Fostamatinib in Brazil

February 4, 2024 | finance.yahoo.com

Knight Therapeutics Inc.'s (TSE:GUD) top owners are retail investors with 43% stake, while 23% is held by private companies

January 31, 2024 | finance.yahoo.com

G2S2 CAPITAL INC. ANNOUNCES INCREASED INVESTMENT IN KNIGHT THERAPEUTICS INC.

November 12, 2023 | markets.businessinsider.com

RBC Capital Keeps Their Buy Rating on Knight Therapeutics (KHTRF)

November 11, 2023 | markets.businessinsider.com

Knight Therapeutics: Strong Q3 Results and Positive Outlook Drive Buy Rating

November 9, 2023 | msn.com

Knight Therapeutics reports Q3 results

November 2, 2023 | finance.yahoo.com

Notice of Knight Therapeutics' Third Quarter 2023 Results Conference Call

October 30, 2023 | finance.yahoo.com

Knight Therapeutics (TSE:GUD) investors are sitting on a loss of 44% if they invested five years ago

October 3, 2023 | prnewswire.com

Knight Therapeutics Inc. ocupa el puesto 90 en la quinta clasificación anual de The Globe and Mail de Canada's Top Growing Companies.

October 3, 2023 | prnewswire.com

Knight Therapeutics Inc. ocupa a 90ª posição no quinto ranking anual das Empresas de Maior Crescimento do Canadá (Canada's Top Growing Companies) segundo a The Globe and Mail.

September 29, 2023 | finance.yahoo.com

Executive Chairman of Knight Therapeutics Jonathan Goodman Buys More Stock

August 10, 2023 | markets.businessinsider.com

Knight Therapeutics (KHTRF) Receives a Hold from Stifel Nicolaus

August 3, 2023 | financialpost.com

Notice of Knight Therapeutics’ Second Quarter 2023 Results Conference Call

July 12, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Oculis Holding (OCS) and Knight Therapeutics (OtherKHTRF)

May 15, 2023 | markets.businessinsider.com

RBC Capital Sticks to Its Buy Rating for Knight Therapeutics (KHTRF)

May 11, 2023 | finance.yahoo.com

Knight Therapeutics Reports First Quarter 2023 Results

May 10, 2023 | finance.yahoo.com

Knight Therapeutics Inc. announces voting results from the Annual General Meeting

May 2, 2023 | theglobeandmail.com

Closing Bell: Knight Therapeutics Inc flat on Tuesday (GUD)

See More Headlines

Receive KHTRF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Knight Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 4/20/2024
Next Earnings (Estimated): 5/09/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: Drug Manufacturers - Specialty & Generic
Sub-Industry: N/A
Current Symbol: OTCMKTS:KHTRF
CUSIP: N/A
CIK: N/A
Web: www.gud-knight.com
Phone: (514) 484-4483
Fax: N/A
Employees: 725
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $7.50
High Stock Price Target: $7.50
Low Stock Price Target: $7.50
Potential Upside/Downside: +79.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

Mr. Jonathan Ross Goodman B.A. (Age 55)
L.L.B., M.B.A., Executive Chairman
Comp: $184.76k
Ms. Samira Sakhia BCom (Age 56)
CA, CPA, MBA, President, CEO & Director
Comp: $496.45k
Mr. Arvind Utchanah
Chief Financial Officer
Ms. Amal Khouri B.Sc.
M.B.A., Chief Business Officer
Mr. Jeff Martens
Global Vice President of Commercial
Mr. Stephani Saverio
Vice President of Business Development
Mr. Leopoldo Bosano
Vice-President of Manufacturing & Operations
Ms. Monica Percario
Global Vice President of Scientific Affairs
Mr. Henrique Dias
Global Director of Marketing
Ms. Susan Caroline Emblem
Global Vice President of Human Resources

Key Competitors

View All Competitors

KHTRF Stock Analysis - Frequently Asked Questions

Should I buy or sell Knight Therapeutics stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Knight Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" KHTRF shares.
View KHTRF analyst ratings or view top-rated stocks.
What is Knight Therapeutics' stock price target for 2024?: 1 analysts have issued 12 month price objectives for Knight Therapeutics' stock. Their KHTRF share price targets range from $7.50 to $7.50. On average, they predict the company's stock price to reach $7.50 in the next year. This suggests a possible upside of 79.0% from the stock's current price.
View analysts price targets for KHTRF or view top-rated stocks among Wall Street analysts.
How have KHTRF shares performed in 2024?: Knight Therapeutics' stock was trading at $3.96 on January 1st, 2024. Since then, KHTRF stock has increased by 5.8% and is now trading at $4.19.
View the best growth stocks for 2024 here.
Are investors shorting Knight Therapeutics?: Knight Therapeutics saw a decline in short interest in the month of March. As of March 15th, there was short interest totaling 209,300 shares, a decline of 10.4% from the February 29th total of 233,600 shares. Based on an average daily trading volume, of 6,200 shares, the short-interest ratio is presently 33.8 days.
View Knight Therapeutics' Short Interest.

When is Knight Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our KHTRF earnings forecast.
How do I buy shares of Knight Therapeutics?: Shares of KHTRF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:KHTRF) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Knight Therapeutics (KHTRF) Stock Price, News & Analysis

About Knight Therapeutics Stock (OTCMKTS:KHTRF)

KHTRF Stock Price History

KHTRF Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

KHTRF Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info